Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHA:600613)
China · Delayed Price · Currency is CNY 4.730
-0.010 (-0.21%)
Jun 18, 2026, 3:00 PM CST
SHA:600613 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,895 | 1,952 | 2,048 | 2,340 | 2,388 | 2,300 |
Other Revenue | 0.62 | 0.62 | 0.51 | 0.68 | 0.22 | 2.92 |
| 1,895 | 1,952 | 2,049 | 2,341 | 2,389 | 2,303 | |
Revenue Growth (YoY) | -3.01% | -4.71% | -12.48% | -2.00% | 3.72% | 26.61% |
Cost of Revenue | 1,065 | 1,089 | 1,097 | 1,189 | 1,125 | 918.13 |
Gross Profit | 830.24 | 863.82 | 951.71 | 1,152 | 1,263 | 1,385 |
Selling, General & Admin | 684.17 | 718.19 | 784.63 | 1,002 | 1,097 | 1,232 |
Research & Development | 29.62 | 30.24 | 32.89 | 32.3 | 45.99 | 50.95 |
Other Operating Expenses | 27.64 | 25.93 | 24.58 | 26.51 | 29.62 | 27.22 |
Operating Expenses | 761.43 | 794.18 | 858.28 | 1,025 | 1,178 | 1,294 |
Operating Income | 68.81 | 69.64 | 93.43 | 126.37 | 85.79 | 90.69 |
Interest Expense | -9.96 | -10.07 | -12.8 | -14.76 | -17.37 | -8.34 |
Interest & Investment Income | 11.34 | 10.43 | 10.85 | 5.97 | 8.17 | 30.51 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0.12 | 0 | 0 | -0 |
Other Non Operating Income (Expenses) | -2.95 | -1.94 | -3.62 | 11.79 | -13.91 | 6.17 |
EBT Excluding Unusual Items | 67.25 | 68.08 | 87.74 | 129.37 | 62.69 | 119.03 |
Impairment of Goodwill | - | - | - | -55.21 | - | - |
Gain (Loss) on Sale of Investments | 1.05 | 0.55 | -0.02 | 0.9 | - | - |
Gain (Loss) on Sale of Assets | 0.22 | 0.22 | -0.37 | 0.17 | -5.23 | -0 |
Asset Writedown | -0.71 | - | -1.47 | -0.47 | -2.72 | -26.72 |
Other Unusual Items | 2.32 | 2.03 | 1.7 | 8.66 | 8.49 | 7.29 |
Pretax Income | 70.13 | 70.87 | 87.58 | 83.41 | 63.23 | 99.6 |
Income Tax Expense | 33.98 | 31.04 | 21.5 | 25.15 | 14.93 | 31.64 |
Earnings From Continuing Operations | 36.14 | 39.84 | 66.08 | 58.26 | 48.29 | 67.96 |
Minority Interest in Earnings | -0.01 | -1.59 | 5.31 | -1.26 | 0.25 | 1.66 |
Net Income | 36.13 | 38.24 | 71.39 | 57 | 48.55 | 69.62 |
Net Income to Common | 36.13 | 38.24 | 71.39 | 57 | 48.55 | 69.62 |
Net Income Growth | -42.13% | -46.43% | 25.24% | 17.41% | -30.27% | - |
Shares Outstanding (Basic) | 582 | 546 | 549 | 518 | 539 | 536 |
Shares Outstanding (Diluted) | 582 | 546 | 549 | 518 | 539 | 536 |
Shares Change (YoY) | 11.06% | -0.51% | 5.97% | -3.94% | 0.72% | 0.46% |
EPS (Basic) | 0.06 | 0.07 | 0.13 | 0.11 | 0.09 | 0.13 |
EPS (Diluted) | 0.06 | 0.07 | 0.13 | 0.11 | 0.09 | 0.13 |
EPS Growth | -47.89% | -46.15% | 18.18% | 22.22% | -30.77% | - |
Free Cash Flow | 169.45 | 91.26 | 171.39 | 191.08 | 292.59 | 98.3 |
Free Cash Flow Per Share | 0.29 | 0.17 | 0.31 | 0.37 | 0.54 | 0.18 |
Dividend Per Share | 0.070 | 0.070 | 0.150 | 0.100 | 0.100 | 0.100 |
Dividend Growth | -53.33% | -53.33% | 50.00% | - | - | - |
Gross Margin | 43.80% | 44.25% | 46.45% | 49.20% | 52.90% | 60.13% |
Operating Margin | 3.63% | 3.57% | 4.56% | 5.40% | 3.59% | 3.94% |
Profit Margin | 1.91% | 1.96% | 3.48% | 2.44% | 2.03% | 3.02% |
Free Cash Flow Margin | 8.94% | 4.67% | 8.37% | 8.16% | 12.25% | 4.27% |
EBITDA | 142.11 | 143.97 | 171.83 | 207.57 | 170.59 | 147.2 |
EBITDA Margin | 7.50% | 7.37% | 8.39% | 8.87% | 7.14% | 6.39% |
D&A For EBITDA | 73.31 | 74.33 | 78.41 | 81.2 | 84.8 | 56.51 |
EBIT | 68.81 | 69.64 | 93.43 | 126.37 | 85.79 | 90.69 |
EBIT Margin | 3.63% | 3.57% | 4.56% | 5.40% | 3.59% | 3.94% |
Effective Tax Rate | 48.46% | 43.79% | 24.55% | 30.15% | 23.62% | 31.76% |
Revenue as Reported | 1,895 | 1,952 | 2,049 | 2,341 | 2,389 | 2,303 |